The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines

Cells - Tập 9 Số 8 - Trang 1775
Roxan F.C.P. Helderman1,2, Daan R. Löke1, Jan Verhoeff3, Hans M. Rodermond2, Gregor G. W. van Bochove2, Menno Boon2, Sanne van Kesteren2, Juan J. García‐Vallejo3, H. Petra Kok1, Pieter J. Tanis4, Nicolaas A.P. Franken1,2, Johannes Crezee1, Arlene L. Oei1,2
1Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
2Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers (UMC), University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
3Department of Molecular Cell Biology & Immunology, Amsterdam Infection & Immunity Institute and Cancer Center Amsterdam, Amsterdam UMC, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands
4Department for Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands

Tóm tắt

Cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment with curative intent for peritoneal metastasis of colorectal cancer (CRC). Currently, there is no standardized HIPEC protocol: choice of drug, perfusate temperature, and duration of treatment vary per institute. We investigated the temperature-dependent effectiveness of drugs often used in HIPEC. Methods: The effect of temperature on drug uptake, DNA damage, apoptosis, cell cycle distribution, and cell growth were assessed using the temperature-dependent IC50 and Thermal Enhancement Ratio (TER) values of the chemotherapeutic drugs cisplatin, oxaliplatin, carboplatin, mitomycin-C (MMC), and 5-fluorouracil (5-FU) on 2D and 3D CRC cell cultures at clinically relevant hyperthermic conditions (38–43 °C/60 min). Results: Hyperthermia alone decreased cell viability and clonogenicity of all cell lines. Treatment with platinum-based drugs and MMC resulted in G2-arrest. Platinum-based drugs display a temperature-dependent synergy with heat, with increased drug uptake, DNA damage, and apoptosis at elevated temperatures. Apoptotic levels increased after treatment with MMC or 5-FU, without a synergy with heat. Conclusion: Our in vitro results demonstrate that a 60-min exposure of platinum-based drugs and MMC are effective in treating 2D and 3D CRC cell cultures, where platinum-based drugs require hyperthermia (>41 °C) to augment effectivity, suggesting that they are, in principle, suitable for HIPEC.

Từ khóa


Tài liệu tham khảo

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492

Brenner, 2014, Colorectal cancer, Lancet, 383, 1490, 10.1016/S0140-6736(13)61649-9

Mehlen, 2006, Metastasis: A question of life or death, Nat. Rev. Cancer, 6, 449, 10.1038/nrc1886

Jayne, 2002, Peritoneal carcinomatosis from colorectal cancer, Br. J. Surg., 89, 1545, 10.1046/j.1365-2168.2002.02274.x

Sugarbaker, 2014, Colorectal cancer: Prevention and management of metastatic disease, Biomed. Res. Int., 2014, 782890, 10.1155/2014/782890

Huang, 2015, Impacts of low peritoneal cancer index on the survival outcomes of patient with peritoneal carcinomatosis of colorectal origin, Int. J. Surg., 23, 181, 10.1016/j.ijsu.2015.08.078

Pelz, J.O., Chua, T.C., Esquivel, J., Stojadinovic, A., Doerfer, J., Morris, D.L., Maeder, U., Germer, C.T., and Kerscher, A.G. (2010). Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer, 10.

Glehen, 2010, Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1290 patients, Cancer, 116, 5608, 10.1002/cncr.25356

Glehen, 2004, Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia, Lancet Oncol., 5, 219, 10.1016/S1470-2045(04)01425-1

Jung, 1982, Interaction of thermotolerance and thermosensitization induced in CHO cells by combined hyperthermic treatments at 40 and 43 degrees C, Radiat. Res., 91, 433, 10.2307/3575883

Hildebrandt, 2002, The cellular and molecular basis of hyperthermia, Crit. Rev. Oncol. Hematol., 43, 33, 10.1016/S1040-8428(01)00179-2

Helderman, R., Loke, D.R., Kok, H.P., Oei, A.L., Tanis, P.J., Franken, N., and Crezee, J. (2019). Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers (Basel), 11.

Avendaño, C., and Menéndez, J.C. (2015). Chapter 6–Anticancer drugs that interact with the DNA minor groove. Medicinal Chemistry of Anticancer Drugs, Elsevier. [2nd ed.].

Kusamura, 2008, Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy, J. Surg. Oncol., 98, 247, 10.1002/jso.21051

Dilruba, 2016, Platinum-based drugs: Past, present and future, Cancer Chemother. Pharmacol., 77, 1103, 10.1007/s00280-016-2976-z

Dasari, 2014, Cisplatin in cancer therapy: Molecular mechanisms of action, Eur. J. Pharmacol., 740, 364, 10.1016/j.ejphar.2014.07.025

Galanski, 2006, Recent developments in the field of anticancer platinum complexes, Recent Pat. Anticancer. Drug Discov., 1, 285, 10.2174/157489206777442287

Calvert, 1982, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II, Cancer Chemother. Pharmacol., 9, 140, 10.1007/BF00257742

Woynarowski, 2000, Oxaliplatin-induced damage of cellular DNA, Mol. Pharmacol., 58, 920, 10.1124/mol.58.5.920

Wheate, 2010, The status of platinum anticancer drugs in the clinic and in clinical trials, Dalton Trans., 39, 8113, 10.1039/c0dt00292e

Focaccetti, C., Bruno, A., Magnani, E., Bartolini, D., Principi, E., Dallaglio, K., Bucci, E.O., Finzi, G., Sessa, F., and Noonan, D.M. (2015). Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS ONE, 10.

Guinney, 2015, The consensus molecular subtypes of colorectal cancer, Nat. Med., 21, 1350, 10.1038/nm.3967

Ubink, 2018, Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases, Br. J. Surg., 105, e204, 10.1002/bjs.10788

Linnekamp, 2018, Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models, Cell Death Differ., 25, 616, 10.1038/s41418-017-0011-5

Kastan, 1991, Participation of p53 protein in the cellular response to DNA damage, Cancer Res., 51, 6304

Riccardi, 2006, Analysis of apoptosis by propidium iodide staining and flow cytometry, Nat. Protoc., 1, 1458, 10.1038/nprot.2006.238

Oei, 2015, Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis, Cancer Res., 75, 5120, 10.1158/0008-5472.CAN-15-0816

Kotecha, N., Krutzik, P.O., and Irish, J.M. (2010). Web-based analysis and publication of flow cytometry experiments. Current Protocols in Cytometry, John Wiley and Sons Inc.. Chapter 10, Unit 10–17.

Franken, 2006, Clonogenic assay of cells in vitro, Nat. Protoc., 1, 2315, 10.1038/nprot.2006.339

Franken, 2011, Comparison of RBE values of high-LET alpha-particles for the induction of DNA-DSBs, chromosome aberrations and cell reproductive death, Radiat. Oncol., 6, 64, 10.1186/1748-717X-6-64

Luo, 2017, Hyperthermia exposure induces apoptosis and inhibits proliferation in HCT116 cells by upregulating miR-34a and causing transcriptional activation of p53, Exp. Ther. Med., 14, 5379

Dewey, 1977, Cellular responses to combinations of hyperthermia and radiation, Radiology, 123, 463, 10.1148/123.2.463

Yan, 2010, A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy, World J. Gastrointest. Oncol., 2, 109, 10.4251/wjgo.v2.i2.109

Sorensen, 2019, Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei, Clin. Exp. Metastasis, 36, 511, 10.1007/s10585-019-09991-0

Jansen, 2004, The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines, Eur. Urol., 46, 670, 10.1016/j.eururo.2004.06.009

Joseph, 1997, Sensitive and convenient high-performance liquid chromatographic method for the determination of mitomycin C in human plasma, J. Chromatogr. B Biomed. Sci. Appl., 698, 261, 10.1016/S0378-4347(97)00291-0

Dalton, 1989, High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urine, J. Chromatogr., 495, 330, 10.1016/S0378-4347(00)82641-9

Eksborg, 1983, Liquid chromatographic determination of mitomycin C in human plasma and urine, J. Chromatogr., 274, 263, 10.1016/S0378-4347(00)84429-1

Ubink, 2019, Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy, Br. J. Surg., 106, 1404, 10.1002/bjs.11206

Esquivel, 2014, The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery, J. Surg. Oncol., 110, 779, 10.1002/jso.23722

Reinacher-Schick, A., Schulmann, K., Modest, D.P., Bruns, N., Graeven, U., Jaworska, M., Greil, R., Porschen, R., Arnold, D., and Schmiegel, W. (2012). Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. BMC Cancer, 12.

Quenet, 2018, A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7, J. Clin. Oncol., 36, LBA3503, 10.1200/JCO.2018.36.18_suppl.LBA3503

Klaver, 2019, Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial, Lancet Gastroenterol. Hepatol., 4, 761, 10.1016/S2468-1253(19)30239-0

Ceelen, 2019, HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?, Eur. J. Surg. Oncol., 45, 400, 10.1016/j.ejso.2018.10.542

Ceelen, 2019, Colorectale peritoneale metastasen: Is er nog plaats voor chirurgie en HIPEC?, Onco Hemato, 13, 1

Faivre, 1999, Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines, Cancer Chemoth. Pharmacol., 44, 117, 10.1007/s002800050955

Johnsson, 2005, In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line, Acta Oncol., 44, 687, 10.1080/02841860500247552

Kornmann, 2000, Oxaliplatin exerts potent in vitro cytotoxicity in colorectal and pancreatic cancer cell lines and liver metastases, Anticancer Res., 20, 3259

Hompes, 2014, The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study, J. Surg. Oncol., 109, 527, 10.1002/jso.23546

Wisselink, 2019, Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer, Crit. Rev. Oncol. Hematol., 142, 119, 10.1016/j.critrevonc.2019.06.014

Goodman, 2016, Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy, J. Gastrointest. Oncol., 7, 45

Jacquet, 1998, Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies, Oncology, 55, 130, 10.1159/000011847

Murata, 2018, 5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer, J. Surg. Oncol., 117, 671, 10.1002/jso.24906

Shimizu, 2014, Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study, Mol. Clin. Oncol., 2, 399, 10.3892/mco.2014.244

Laffeber, 2017, The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination, Oncotarget, 8, 44593, 10.18632/oncotarget.17861

Krawczyk, 2011, Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition, Proc. Natl. Acad. Sci. USA, 108, 9851, 10.1073/pnas.1101053108

Urano, 2002, Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitro, Int. J. Hyperth., 18, 307, 10.1080/02656730210123534

Ceha, 1999, Inactivation of p53 and of pRb protects human colorectal carcinoma cells against hyperthermia-induced cytotoxicity and apoptosis, J. Cancer. Res. Clin. Oncol., 125, 549, 10.1007/s004320050315

Franken, 2001, Wild-type p53-function is not required for hyperthermia-enhanced cytotoxicity of cisplatin, Int. J. Hyperth., 17, 337, 10.1080/02656730117221

Cui, 2017, Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity, J. Inorg. Biochem., 177, 249, 10.1016/j.jinorgbio.2017.04.022

Buss, 2018, Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells, Metallomics, 10, 414, 10.1039/C7MT00334J

Thông tin
Thông tin xuất bản

Cells

Tập 9 Số 8

1775

Thông tin tác giả